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OBJECTIVES: The Recent ISPOR Task Force on Modelling emphasised the 
importance of conceptualising and validating models. We report a new model of 
COPD that has been founded on a conceptual model designed by a panel of 
experts prior to data analysis, implemented using a novel linked-equation 
approach and internally validated with the data used to generate the model 
parameters. METHODS: An expert panel, including clinicians and decision 
modellers with experience of COPD, developed a conceptual model including 
causal relationships between core components of the disease (lung function, 
exacerbations, symptoms and exercise capacity) and final health outcomes and 
resource use (survival, quality of life, cost). Risk equations describing these 
relationships were estimated from a three-year longitudinal study (ECLIPSE), 
with bi-directional relationships in the conceptual model handled by using 
lagged variables. The model was implemented as a linked-equation model 
enabling direct estimation of health service costs and quality adjusted life-years 
for cohorts of COPD patients over a lifetime time horizon. Internal validation was 
undertaken by comparing three years of predicted cohort experience with results 
reported for ECLIPSE. RESULTS: At three years, the model predicted a survival 
rate of 90.7%, an average annual exacerbation rate of 0.95 and an annual FEV1 
decline of 38.8ml per year, which all fell within the confidence limits of the 
original ECLIPSE data. Projections of the risk equations over time permitted 
extrapolation to patient lifetimes. Potential treatment effects on intermediate 
risk factors lead to predicted effects on final model outcomes. CONCLUSIONS: 
We have conceptualised, implemented and internally validated a new form of 
model for COPD based on a series of linked equations. This model is capable of 
predicting COPD outcomes for a variety of potential treatment effects on 
intermediate risk factors. Further validation of short and long-term predictions 
of the model is required.  
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COST EFFECTIVENESS OF BUDESONIDE/FORMOTEROL VERSUS 
FLUTICASONE/SALMETEROL FROM A SWEDISH HEALTH CARE PERSPECTIVE 
BASED ON REAL-WORLD EFFECTIVENESS AND SAFETY IN PATIENTS WITH 
COPD  
Hedegaard M1, Janson C2, Lisspers K2, Ställberg B2, Johansson G2, Jørgensen L3, Larsson K4 
1AstraZeneca, Copenhagen S, Denmark, 2Uppsala University, Uppsala, Sweden, 3AstraZeneca, 
Södertälje, Sweden, 4Karolinska Institutet, Stockholm, Sweden  
OBJECTIVES: Fixed combinations of inhaled corticosteroids and long-acting β2-
agonists are frequently used to reduce exacerbations for patients with chronic 
obstructive pulmonary disease (COPD), but some treatments with inhaled 
glucocorticosteroids are linked with increased risk of pneumonia. The objective of 
this study was to evaluate the cost-effectiveness of budesonide/formoterol relative 
to fluticasone/salmeterol based on both real-world effectiveness and safety data 
(NCT01146392) from a Swedish health care perspective. METHODS: Resource use, 
effectiveness and safety data were collected retrospectively from primary care 
medical records’ data for patients with a diagnosis of COPD (J44) and merged with 
Swedish hospital, drug, and cause of death register data from 01 January 1999 to 31 
December 2009. Propensity score matching on 31 variables two years pre-index was 
done at the index date (first prescription of fixed combination post COPD diagnosis) 
to minimize bias. The effectiveness variable was the number of exacerbations 
avoided. Exacerbations were defined as hospitalisations and emergency room visits 
for COPD, glucocorticosteroids prescriptions and/or antibiotics prescriptions for 
respiratory tract infections. Direct costs were calculated by applying year 2011 
Swedish unit costs to the annual resource use for exacerbations as well as 
pneumonia-related hospitalisations (J10-18). Bootstrapping and one-way sensitivity 
analyses were used to quantify uncertainty around estimates. RESULTS: The 
annual exacerbation rate and the average annual hospitalisation days 
(exacerbation- and/or pneumonia-related) were 0.80 and 0.87 for patients treated 
with budesonide/formoterol (n=2734) and 1.09 and 1.36 for patients treated with 
fluticasone/salmeterol (n=2734, 27% and 36% reduction respectively, p<0.0001). 
Treatment with budesonide/formoterol was cost-saving compared with 
fluticasone/salmeterol (total average annual cost per patient was SEK 12,495 [€1384] 
and SEK 16,301 [€1805], respectively). Sensitivity analyses showed that results were 
robust. CONCLUSIONS: Budesonide/formoterol was the dominant strategy (more 
effective at lower cost) compared to fluticasone/salmeterol for the treatment of 
patients with COPD based on real-world effectiveness and safety data.  
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ECONOMIC EVALUATION OF LINEZOLID VERSUS VANCOMYCIN FOR 
VENTILATOR-ASSOCIATED PNEUMONIA PATIENTS IN GUATEMALA  
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OBJECTIVES: Ventilator-associated pneumonia (VAP) is associated with 
increasing intensive care unit (ICU) admissions, morbidity and length of stay 
(LOS) as it’s one of the most common nosocomial infections in the ICU; raising 
overall costs. Literature suggests costs could be significantly reduced by using 
the most efficient empiric therapy. The aim of this study was to assess the cost-
effectiveness (CE) of linezolid against generic vancomycin as an empiric therapy 
for adult VAP patients, from the public health care perspective. METHODS: A 
cohort of patients with VAP in the ICU was simulated using a decision-tree 
model to compare costs and effectiveness of linezolid (600 mg/12 hours) and 
vancomycin (15 mg/kg/12 hours) (basecase). Effectiveness measures were: 
microbiological success rates, mortality rates, and ICU and ward LOS. The model 
used a 12-week time horizon and only direct medical costs were considered 
(inpatient costs, medication expenses, adverse events costs, hematologic and 
gastrointestinal tests) Effectiveness and epidemiologic data were retrieved from 
published literature. Local costs (2012 US$) were gathered from the Social 
Security of Guatemala official databases. Monte Carlo probabilistic sensitivity 
analysis (PSA) was constructed. RESULTS: Linezolid resulted as the most 
effective and less expensive option for VAP adult patients. Clinical success rate 
was higher with linezolid (64.4%) against vancomicyn (56.1%). Mean expected 
ICU LOS was 18 days for linezolid and 22 days for vancomycin, ward LOS was 9 
and 10 days with linezolid and vancomycin, respectively. Mortality rate was 
found lower in the linezolid arm (10.13%) in comparison to vancomycin (15.74%). 
Overall costs per patient were $23,089.15 with linezolid and $26,384.63 with 
vancomycin. In the CE incremental analysis, linezolid appeared as the cost-
saving option. PSA outcomes support the robustness of these findings. 
CONCLUSIONS: Linezolid resulted as the cost-saving therapy for treating VAP 
adult patients in ICU in Guatemala.  
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THE HUMANISTIC AND ECONOMIC IMPACT OF FOLLOWING EVIDENCE-BASED 
ASTHMA CONTROLLER THERAPY: A SIMULATION STUDY  
Zafari Z, Sadatsafavi M, FitzGerald M, Lynd L, Marra C 
University of British Columbia, Vancouver, BC, Canada  
OBJECTIVES: To quantify the potential US societal benefits, in terms of health 
care costs and quality of life, of improving gaps in care by increasing compliance 
with guideline-driven asthma management relative to the current level of care 
(i.e. status quo) METHODS: A Markov model of asthma was created to simulate 
the natural history of asthma and the potential impact of improved compliance 
to medications over a 20 year time horizon. The current state of asthma care 
(status quo) in terms of the proportion of individuals who receive regular, 
irregular, and no controller treatment, along with parameters representing the 
natural history of asthma, was estimated from the literature. Total costs, 
exacerbation rates, and quality-adjusted life years (QALY) of a status quo 
strategy was compared with a hypothetical situation in which each individual 
receives regular controller medications according to the current 
recommendations (ideal strategy). All costs and outcomes were discounted at a 
rate of 0.02. RESULTS: Under the status quo, each individual with asthma will 
generate, on average, US $9681 in total medical costs and 14.3 QALYs over 20 
years. By following guidelines, average total costs will increase to $18,446 
producing 14.6 QALYs. The discounted number of exacerbations over 20 years for 
the status quoand optimal strategies will be 10 and 4.6, respectively. The 
incremental cost-effectiveness ratio (ICER) of the ideal strategy compared to 
status quo was estimated to be $29,217 US per QALY gained. CONCLUSIONS: 
There is a significant opportunity to reduce the socio economic burden of 
asthma in the US with greater adherence to evidence-based asthma 
management guidelines. While improved adherence to guidelines increases 
some costs (e.g. medications), the substantial return on investment associated 
with improved adherence will likely offset the extra costs.  
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COST-EFFECTIVENESS OF MOMETASONE FUROATE NASAL SPRAY IN THE 
TREATMENT OF RHINOSINUSITIS IN MEXICO  
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OBJECTIVES: Little information exists on the acute treatment provided for 
rhinosinusitis and its associated costs. This study assessed the cost-effectiveness of 
mometasone furoate versus amoxicillin for the treatment of rhinosinusitis in 
Mexico from a health care perspective. METHODS: A decision tree model was 
constructed using decision analytical techniques. Data sources included published 
literature, clinical trials, official price/tariff lists, and Delphi panel data. The 
comparators were mometasone furoate 200μg twice daily and amoxicillin 500mg 
three times daily. This study further do not included MFNS 200μg once daily as a 
treatment arm because it was not found to be superior to amoxicillin. The time 
horizon was 2 weeks. The effectiveness outcomes of the study were modeled as 
changes in the Major Symptom Score (MSS). MSS consists of five questions 
concerning rhinorrhoea, post-nasal drip, nasal congestion, sinus headache, and 
facial pain. Costs were valued in US dollar, year 2012 values. One-way and 
probabilistic sensitivity analyses were conducted to evaluate uncertainty in the 
results. RESULTS: The projected costs were US$ 258 with Mometasone furoate and 
$US 272 with.The benefits were 0.52 with Mometasone furoate, 0.45 with 
Amoxicilin. Mometasone furoate was associated with a cost savings per patient of 
US$ 13.92 versus amoxicillin over a period of 2 weeks from a health care 
perspective. The incremental cost-effectiveness ratio for Mometasone furoate 
dominated Amoxicilin. Sensitivity analysis confirmed the overall cost savings and 
gains in effectiveness. CONCLUSIONS: Our analysis suggests Mometasone Furoate 
improves health outcomes in a cost-effective manner compared with Amoxicilin, 
and highlights the importance of using evidence-based effectiveness estimates in 
economic studies of rhinosinusitis therapies  
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COMPARATIVE PHARMACOECONOMIC ANALYSIS OF 
BUDESONIDE/FORMOTEROL MAINTENANCE AND RELIEVER THERAPY IN THE 
TREATMENT OF BRONCHIAL ASTHMA IN RUSSIAN FEDERATION  
Yagudina R, Kulikov A, Novikov I 
I.M. Sechenov First Moscow State Medical University, Moscow, Russia  
OBJECTIVES: The purpose of this research was to determine the cost-
effectiveness of budesonide/formoterol maintenance and reliever therapy of 
bronchial asthma in condition of Russian health care system. Total medical 
expenses and effectiveness in term of exacerbations prevention were compared 
for budesonide/formoterol maintenance and reliever therapy, 
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salmeterol/fluticasone, beclametasone/formoterol, budesonide/formoterol (free 
adjustable combination) and conventional best practice. METHODS: For 
construction of pharmacoeconomic model a set of comparative randomised 
controlled trials for each therapeutic alternative were identified. From them data 
on clinical effectiveness in form of asthma exacerbations avoided for 1 patient-
year were extracted. The analysis was conducted from the perspective of 
Russian health care system. Respectively the cost of the following resources was 
accounted: alternative compared, concomitant pharmacotherapy, cost of 
hospitalizations, cost of ambulkatory visits. Analysis was performed in the form 
of cost-effectiveness analysis the exacerbation prevented being the measure of 
effectiveness. RESULTS: The data of the research illustrates that 
budesonide/formoterol maintenance and reliever therapy for asthma patients 
provides a significant health improvement from the perspective of preventing 
exacerbations. Simultaneosly budesonide/formoterol maintenance and reliever 
therapy demonstrates better cost-effectiveness than alternatives compared. The 
CER index in relation to cost of asthma control during the year (absence  
of exacerbations) for budesonide/formoterol maintenance and reliever therapy 
was 147785 rub. respective figures for salmeterol/fluticasone, beclametasone/ 
formoterol, budesonide/formoterol (free adjustable combination) and 
conventional best practice were 383622 rub., 169245 rub., 227592 rub., 219233 
rub., respectively. CONCLUSIONS: Budesonide/formoterol fixed combination for 
maintenance and reliever therapy turned to be cost-effective therapeutic 
alternative for asthma control in adult patients in conditions of Russian health 
care system.  
 
PRS27  
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OBJECTIVES: Acute exacerbations of chronic bronchitis (AECB) are a leading 
cause of morbi-mortality and medical resources consumption. This study  
was aimed to estimate the economic and health consequences of first line 
antibiotics in the management of AECB and it´s recurrences, under the setting of 
a representative Mexican health care institution. METHODS: Two models  
were developed: a decision tree for acute events (tree month horizon) and a two-
state, one-quarter cycle Markov for recurrences (one year horizon). The 
competing alternatives (listed in the national formulary) were: moxifloxacin 400 
mg/day, levofloxacin 500 mg/day, ceftriaxone 1000 mg/day, clarithromycin 1000 
mg/day, cefuroxime 1000 mg/day and, not listed in the national formulary, 
gemifloxacin 320 mg/day. The clinical success rate and months free of 
recurrences (effectiveness measures) were extracted from international 
literature. Resource use was extracted from 117 clinical files (adult patients) 
treated at Instituto Mexicano del Seguro Social (IMSS).The cost of antibiotics 
were extracted from IMSS´s sources (except of gemifloxacin, provided by the 
manufacturer); the unit cost of physician visits, diagnostic tests, emergency 
room, in-patient, intensive care unit were the official for IMSS. Costs are 
expressed in 2012 U$. One-way sensitivity analysis was performed. RESULTS: 
The clinical success rates were between 97.5% (gemifloxacin) and 83.1% 
(cefuroxime), the costs per patient-per AECB were proportional: $3,375.6 
(gemifloxacin) and $4825.1% (cefuroxime), gemifloxacin dominated progressively 
ceftriaxone, moxifloxacin, levofloxacin, clarithromycin and cefuroxime. 
Regarding AECB recurrences, clarithromycin represented the highest cost and 
lowest time free of recurrence: $8198.99 and 10.28 months, respectively, whereas 
gemifloxacin represented the opposite: $3,325.73 and 11.015 months, 
respectively. The length of stay were between 6.22 (gemifloxacin) and 10.3 days 
(cefuroxime). The results were robust to +10% acquisition cost, +5% adverse 
events incidence and -5% clinical success rate for gemifloxacin. CONCLUSIONS: 
At IMSS setting, gemifloxacin is an alternative that would promote savings in the 
treatment of AECB and it´s recurrences.  
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LONG-TERM HUMIDIFICATION THERAPY IMPROVES QUALITY OF LIFE AND IS 
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OBJECTIVES: To evaluate the cost effectiveness of long-term therapy with high flow 
humidified air supplemented with oxygen as required at 37°C delivered through 
nasal cannulae (long term humidification therapy; LTHT) for patients with 
moderate or severe COPD or bronchiectasis. METHODS: The source was a 12-month 
clinical trial showing that LTHT at a mean duration of 1.6 hours per day reduced 
exacerbation days and improved quality of life assessed by the St. George’s 
Respiratory Questionnaire compared to usual care alone. Resources included the 
LTHT intervention equipment and consumables, relevant hospital admissions, 
general practitioner consultations, Emergency Care presentations and 
pharmaceuticals. Details of consultations and medication usage were obtained 
from patient diaries and hospital admissions from retrospective administrative 
records. Utility values were obtained indirectly from the St Georges Respiratory 
Questionnaire using a published algorithm. The ICUR was estimated over the 
lifetime of the device (5 years) using the bootstrap method with 5000 replications. 
Future costs and benefits were discounted at 3.5% per annum. RESULTS: The 
incremental health state utility over 12 months was estimated at +0.084 (95% CI 
0.003-0.165). Annual costs excluding the intervention were NZ$2329 (95%CI $1249, 
$3409) for the treatment group and NZ$3477 ($712, $6241) for the control group 
(nsd). With the LTHT intervention costed at $10,461 over the lifetime of the device (5 
years) the cost per QALY was NZ$15,615 (95%CI $15,521, $15,709). At a willingness to 
pay (WTP) threshold of NZ$30,000, the probability of LTHT being cost effective was 
89% and at a WTP threshold of $20,000 it was 71%, ranging from 64% to 77% as the 
5-year cost of LTHT equipment and running costs was varied by ±20%. 
CONCLUSIONS: Long term humidification therapy for moderate to severe COPD or 
bronchiectasis is as cost effective as most new pharmaceuticals that are 
reimbursed by the New Zealand government.  
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INTRODUCTION: Childhood asthma is a major public health problem in 
Colombia as in many other countries. In patients entering the second line 
therapy, options in the 5-11 years old category are increase corticosteroids, add 
LABA or add LTRA. In under five years old adding LABA is not an option. There 
are differences in cost and efficacy between these options, to address this issue 
an economic evaluation was done in the context of the National Colombian 
Clinical Practice Guidelines Programme in collaboration with the Colombian 
Pediatric Pneumonology Association. OBJECTIVES: To evaluate the cost 
effectiveness of the second line asthma therapy options in pediatric patients in 
Colombia. METHODS: A Markov model was developed including the following 
health states: controlled asthma, uncontrolled asthma, ambulatory exacerbation, 
exacerbation with hospitalization and therapeutic failure. A restringed social 
perspective was used (health system + out of pocket expenses) with a 3 months 
time horizon. Transition probabilities and utility estimates were derived from 
international literature and validated by a Delphi panel with local Colombian 
experts. Costs were provided by the Colombian MoH. A deterministic and 
probabilistic sensitivity analysis was performed. RESULTS: The LTRA option was 
dominated, being more expensive and less efficacious than increasing 
corticosteroids in both age categories. In the 5-11 years old the ICER comparing 
LABA with corticosteroids was 4.366.343 Colombian pesos (COP) per quality 
adjusted life week (QALW) gained. This ICER is far above the 634.000 COP per 
QALW estimated for a 3 GDP threshold. In the sensitivity analysis these results 
probed to be robust being necessary a 4.400.000 COP per QALW of willingness to 
pay for the LRTA option to start being cost effective. CONCLUSIONS: Increasing 
corticosteroids was the most cost effective option in asthmatic pediatric 
population in Colombia compared to LABA, being LRTA dominated or far above 
the Colombian thresholds.  
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ASSESSMENT OF ADHERENCE TO INHALED CORTICOSTEROID TREATMENT FOR 
ASTHMA: A CROSS-SECTIONAL STUDY FROM DELHI, INDIA  
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OBJECTIVES: Despite the known importance of regular use of inhaled 
corticosteroids (ICS) for asthma control, there is a dearth of adherence literature 
from India. The study aims were to (i) evaluate patients’ self-reported adherence 
to ICS therapy, (ii) identify possible reasons for non-adherence, and (iii) identify 
possible correlations between ICS adherence, medicine beliefs and socio-
demographic factors of asthma patients. METHODS: Adults with previously 
diagnosed asthma (n=200) presenting to the emergency room (March 2009-
December 2009) of a public chest hospital in Delhi for asthma exacerbation 
completed an interviewer-administered questionnaire on socio-demographics, 
clinical history, self-reported adherence, beliefs about causes of disease, 
medicine beliefs and medication adherence after stabilization of their condition. 
RESULTS: Study sample had 51.5% patients in the age group of 30-40 years, 54.0% 
females, 10.0% illiterate, and 62.5% patients earning less than INR 10,000/month 
($185/month). The mean duration of registration with the study hospital was 
5.4±4.4 years and all were prescribed ICS treatment. Self-report on adherence: 
49% took medicines even without symptoms; 91.0% reported they forgot to take 
their medicine “some or lot of times”; 84.0% avoided medicines “some of the 
times”. Important reasons for avoiding medicines were no symptoms (59.5%), 
cost (34.5%), fear of getting dependent (29%), side effects (17%) and social 
inhibition (14.5%). Correlation between self-reported adherence and 
demographic factors, such as age, sex, education and income was calculated. 
The commonly endorsed causes for asthma were pollution (33.5%), poor medical 
care in the past (15.5%), heredity (8.5%), cold climate (7.5%), and diet (5.5%). Non-
adherent behaviors were associated with doubts about the necessity of 
medication and concerns about its potential side effects with long-term use (r=-
0.299, p<0.001). CONCLUSIONS: Adherence to ICS therapy is poor and many 
factors modulate adherence to therapy. These findings lend preliminary support 
for an extended self-regulatory model of treatment adherence, which 
incorporates beliefs about treatment.  
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ADHERENCE AND SATISFACTION WITH ORAL VERSUS OTHER TREATMENTS 
AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
(COPD) IN THE U.S. 2012 NATIONAL HEALTH AND WELLNESS SURVEY  
